Vivos Therapeutics, Inc. (VVOS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 8M 16M 24M Q4 '20: 13.1M Q1 '21: 13.3M Q2 '21: 14.5M Q3 '21: 15.8M Q4 '21: 16.9M Q1 '22: 17.1M Q2 '22: 16.8M Q3 '22: 16.5M Q4 '22: 16M Q1 '23: 16.2M Q2 '23: 15.4M Q3 '23: 14.5M Q4 '23: 13.8M Q1 '24: 13.4M Q2 '24: 14M Q3 '24: 14.6M Q4 '24: 15M Q1 '25: 14.6M Q2 '25: 14.4M Q3 '25: 17.3M Q4 '25: 17.4M Q1 '26: 19.6M Q2 '26: 20.9M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 5M 10M 15M Q4 '20: 10.4M Q1 '21: 10.7M Q2 '21: 11.6M Q3 '21: 12.2M Q4 '21: 12.6M Q1 '22: 12.5M Q2 '22: 11.4M Q3 '22: 10.7M Q4 '22: 10M Q1 '23: 9.8M Q2 '23: 9.3M Q3 '23: 8.6M Q4 '23: 8.3M Q1 '24: 7.9M Q2 '24: 8.4M Q3 '24: 9M Q4 '24: 9M Q1 '25: 8.6M Q2 '25: 8.1M Q3 '25: 9.7M Q4 '25: 10.5M Q1 '26: 12.1M Q2 '26: 12.9M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-30M -20M -10M 0 10M 20M 30M Q4 '20: -12M Q1 '21: -12.9M Q2 '21: -15.5M Q3 '21: -19.2M Q4 '21: -20.4M Q1 '22: -23.6M Q2 '22: -26.5M Q3 '22: -26.4M Q4 '22: -25.1M Q1 '23: -23.4M Q2 '23: -21M Q3 '23: -19.2M Q4 '23: -17.3M Q1 '24: -16.1M Q2 '24: -13.5M Q3 '24: -12.5M Q4 '24: -11.2M Q1 '25: -11.3M Q2 '25: -14.2M Q3 '25: -16.3M Q4 '25: -19.9M Q1 '26: -22.6M Q2 '26: -22.6M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-27M -18M -9M 0 9M 18M 27M Q4 '20: -12.1M Q1 '21: -12.9M Q2 '21: -15.5M Q3 '21: -19.1M Q4 '21: -20.3M Q1 '22: -22.2M Q2 '22: -25.2M Q3 '22: -25.1M Q4 '22: -23.8M Q1 '23: -20.2M Q2 '23: -18.8M Q3 '23: -15.4M Q4 '23: -13.6M Q1 '24: -15.6M Q2 '24: -12M Q3 '24: -12.6M Q4 '24: -11.1M Q1 '25: -11.2M Q2 '25: -14.3M Q3 '25: -17.1M Q4 '25: -21.2M Q1 '26: -25M Q2 '26: -25.5M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 3M 6M 9M Q4 '20: 2.7M Q1 '21: 2M Q2 '21: 1.5M Q3 '21: 918.5K Q4 '21: 600K Q1 '22: 600K Q2 '22: 600K Q3 '22: 600K Q4 '22: 300K Q1 '23: 300K Q2 '23: 300K Q3 '23: 300K Q4 '23: 300K Q1 '24: 300K Q2 '24: 1.6M Q3 '24: 3M Q4 '24: 4.6M Q1 '25: 6M Q2 '25: 6.3M Q3 '25: 7.7M Q4 '25: 6.9M Q1 '26: 7.5M Q2 '26: 8M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q4 '20: -5.7M Q1 '21: -9.1M Q2 '21: -11.8M Q3 '21: -15.2M Q4 '21: -15.7M Q1 '22: -18M Q2 '22: -18.9M Q3 '22: -20.7M Q4 '22: -19.6M Q1 '23: -17M Q2 '23: -15.2M Q3 '23: -12.2M Q4 '23: -11.9M Q1 '24: -10.9M Q2 '24: -11.1M Q3 '24: -12.5M Q4 '24: -12.7M Q1 '25: -14M Q2 '25: -14.4M Q3 '25: -14.4M Q4 '25: -15.3M Q1 '26: -17.5M Q2 '26: -17.1M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q4 '20: -5.8M Q1 '21: -9.5M Q2 '21: -13.5M Q3 '21: -17.3M Q4 '21: -18.1M Q1 '22: -20.2M Q2 '22: -20.4M Q3 '22: -21.8M Q4 '22: -20.5M Q1 '23: -18.1M Q2 '23: -16M Q3 '23: -13M Q4 '23: -12.7M Q1 '24: -11.6M Q2 '24: -11.6M Q3 '24: -13.1M Q4 '24: -13.3M Q1 '25: -14.5M Q2 '25: -15.7M Q3 '25: -15.4M Q4 '25: -17.6M Q1 '26: -19.7M Q2 '26: -19M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 8B 16B 24B Q1 '21: 18.2M Q2 '21: 20.7B Q3 '21: 20.8B Q1 '22: 21.2M Q2 '22: 21.2M Q3 '22: 849.4K Q1 '23: 990.7K Q2 '23: 1.2M Q3 '23: 1.2M Q1 '24: 2.3M Q2 '24: 3.2M Q3 '24: 6.6M Q1 '25: 8.6M Q2 '25: 9.1M Q3 '25: 11M Q1 '26: 14.6M Q2 '26: 17.7M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q4 '20: -1.41 Q1 '21: -1.37 Q3 '22: -7.32 Q4 '22: -11.98 Q1 '23: -13.45 Q2 '23: -17.74 Q3 '23: -13.09 Q4 '23: -11.14 Q1 '24: -11.05 Q2 '24: -7.03 Q3 '24: -5.68 Q4 '24: -2.91 Q1 '25: -1.73 Q2 '25: -1.68 Q3 '25: -1.77 Q4 '25: -2.07 Q1 '26: -2.14 Q2 '26: -1.90 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.